Recombinant Human CTRP2/C1qTNF2 Protein, CF

Recombinant Human CTRP2/C1qTNF2 Induces Phosphorylation of AMPK in C2C12 Differentiated Myocytes. C2C12 differentiated myocytes were treated with Recombinant Human CTRP2/C1qTNF2 (Catalog # 9436‑TN) for 1 hour prior to Western blot analysis.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CTRP2/C1qTNF2 Protein, CF Summary

• Details of Functionality: Measured by its ability to induce phospho AMPK activation in C2C12 mouse differentiated myocytes. 100-300 ng/mL of Recombinant Human CTRP2/C1qTNF2 induces phosphorylation of AMPK.
• Source: Human embryonic kidney cell, HEK293-derived human CTRP2/C1qTNF2 protein

  DYKDDDDK (FLAG tag)

  Human CTRP2/C1qTNF2 (Gly144-Val285) Accession # Q9BXJ5

  GGGGS

  Human CTRP2/C1qTNF2 (Gly144-Val285) Accession # Q9BXJ5

  GGGGS

  Human CTRP2/C1qTNF2 (Gly144-Val285) Accession # Q9BXJ5

  N-terminus

  C-terminus

• Accession #: Q9BXJ5
• N-terminal Sequence: Asp (Flag tag)
• Structure / Form: GS-linked homotrimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 49 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 54-62 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in HEPES and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CTRP2/C1qTNF2 Protein, CF

• C1q and tumor necrosis factor related protein 2
• C1QTNF2
• complement-c1q tumor necrosis factor-related protein 2
• CTRP2
• CTRP2complement C1q tumor necrosis factor-related protein 2
• zacrp2

Background

Complement C1q tumor necrosis factor-related protein 2 (C1qTNF2), also known as CTRP-2 or zacrp2 is an approximately 30 kDa member of the C1q family of secreted proteins (1, 2). Like other members of that family, CTRP2 contains a collagen-like region and one C1q-like domain (3). CTRP2 shares 42% amino acids identity with adiponectin at the presumed functional globular domain (4) and is expressed in stromal vascular cells (5). CTRP2 circulates as a trimeric glycoprotein in plasma (6), and can also form homo-oligomer or hetero-oligomer with other CTRPs (7). C1qTNF2 has been shown to phosphorylate AMPK and ACC in skeletal muscle leading to an increase in glycogen accumulation and fatty acid oxidation (8). C1qTNFs are of clinical interest as diagnostic or therapeutic targets in diseases where energy homeostasis is unbalanced such as obesity, insulin resistance, and type 2 diabetes (2).

1. Hosszu, K.K. et al. (2012) Front. Immunol. 5:3.
2. Seldin, M.M. et al. (2014) Rev. Endocr. Metab. Disord. 15:111.
3. Kim, K.-Y. et al. (2006) FEBS Lett. 580:3953.
4. Wong, G.W et al. (2004). Proc. Natl. Acad. Sci. U.S.A. 101:10302.
5. Schäffler, A. et al. (2012) Trends in Endocrinology and Metabolism. 23:194.
6. Wong, G.W. et al. (2008) Biochem J. 416:161.
7. Peterson, J.M.l. et al. (2014) PLOS one 9:e88535.
8. Schäffler, A. et al. 2007) Trends in Immunology 28:393.

Bioinformatics

• Uniprot:
  • Q9BXJ5()